Business Wire

CHRYSO®Quad: A Range of Admixtures and Services for Complex Local Sands and Aggregates, in Support of the Circular Economy

20.4.2023 12:20:00 EEST | Business Wire | Press release

Share

To support sustainable construction stakeholders, CHRYSO is strengthening its CHRYSO®Quad range and associated services in response to the challenges of the circular economy. CHRYSO promotes the use of complex aggregates sourced locally or from recycled concrete from deconstruction sites.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005807/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CHRYSO®Quad fosters local sourcing of aggregates and sands (Photo: Shutterstock)

Dedicated services to characterize materials and adjust admixture solutions

It all starts with the analysis of sands using the patented CHRYSO®CLEAR Test method, which diagnoses the presence of swelling clay. Then, the dedicated CHRYSO®Quad Lab service allows CHRYSO experts to carry out a precise diagnosis of a series of additional parameters: particle size (to determine the lack or excess of fines), absorption, shape factors, etc.

Additionally, compaction tests are performed in CHRYSO's application laboratories to consider all the parameters of the concrete mix design. Finally, the brand-new digitalized service CHRYSO®Quad App proposes the most suitable admixture solution based on the customer's material characterization (sands and aggregates) and thus broadens the scope of potential supply sources.

The use of complex aggregates and sands while improving concrete performance

The customized CHRYSO®Quad admixture solutions are adjusted according to the available resources of complex sands and aggregates. This allows clients to gain flexibility by integrating new sands and aggregates into their concrete mix and overcome shortages or tensions in material supplies. CHRYSO experts accompany their clients in producing durable and robust concrete that can withstand material variations.

CHRYSO®Quad contributes to the circular economy and reduces the carbon footprint

By anticipating the constraints of quality and availability of local sands and aggregates, CHRYSO®Quad fully embraces a circular economy approach.

CHRYSO®Quad is a development lever for recycling materials from deconstruction, allowing for the recovery and use of recycled aggregates.

The use of local resources also contributes to reducing supply costs and decreasing the carbon footprint associated with the transportation of raw materials.

CHRYSO continues to deploy CHRYSO®Quad

To date, 9 million m3 of concrete have already benefited from CHRYSO®Quad solutions, including on large construction sites around the world. Leveraging its international network of application laboratories, CHRYSO provides answers to the sourcing challenges of aggregates faced by industry stakeholders.

CASE STUDY

With CHRYSO®Quad 870, a concrete industry player manages to use 100% of complex sands in its concrete formulation

To support a client in the south of France in optimizing the sand resources used in its concrete formulation, CHRYSO proposed its CHRYSO®Quad 870 solution, which improved productivity, concrete quality, and allowed for sourcing exclusively from local suppliers.

This industry player supplied his plant with sand from two quarries. A complex crushed sand, sourced from a quarry near the plant. A second "corrective" sand, from another quarry located 60km from the plant. Up to 50% of each sand was used in the different concrete mixes, which ranged from class S3 to S5.

In its specifications, the industry player requested that CHRYSO provides a solution to increase its capacity to use complex sands (with a high content of fines and the presence of clays). Thanks to the CHRYSO®Quad Lab service, sands were recovered and analyzed in the laboratory and in the plants. This allowed CHRYSO to design the customized CHRYSO®Quad 870 product. The first product testing phases were validated on site by sand variability checks carried out by the client using the CHRYSO®CLEAR Test kit.

As a result, the customer has extended the use of CHRYSO®Quad 870 to three other concrete plants and now uses 100% complex sand from a local quarry. The use of a single sand, with a constant dosage, brings a benefit of regularity in the production, reducing the weight of CEM II A cement in the design mix, which represents a 10% reduction of the carbon footprint. In addition, thanks to the exclusive use of short-distance sourcing, 24 lorry journeys per month have been avoided.

ABOUT SAINT-GOBAIN CONSTRUCTION CHEMICALS

Saint-Gobain Construction Chemicals offers cement additives, concrete admixtures and specialty building materials, through the combined activities of Chryso and GCP. Its recent technologies for sustainable construction help reduce energy consumption, lower the carbon footprint of cements and concrete, and foster the circular economy. Leveraging its global manufacturing presence, Saint-Gobain Construction Chemicals serves its customers through local sites in over 40 countries, employing over 2,700 people.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press relations
CHRYSO
Daphnée DECAUDIN
Daphnee.decaudin@chryso.com
+33 6 19 07 64 74

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in their Global Partnership19.2.2026 11:59:00 EET | Press release

GekkoVet, the Finnish leader in AI-powered clinical decision support for veterinarians, and Royal Canin, a global pioneer in pet health through nutrition, announce the launch of their strategic collaboration in Mexico. This marks the first national rollout of their partnership in Latin America, expanding the initiative that began earlier this year with successful deployments in Asia. Royal Canin Mexico is equipping veterinary teams with GekkoVet’s intelligent platform, which provides real-time diagnostic assistance, treatment recommendations, and drug information. The collaboration aims to enhance clinical efficiency, improve patient outcomes, and support veterinarians with evidence-based tools that integrate seamlessly into daily practice. “This launch in Mexico is a major step forward—not just regionally, but globally,” said Johanna Majamaa, DVM and co-founder of GekkoVet. “After strong momentum in Asia, entering Latin America opens a new chapter in our mission to empower veterinaria

Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 11:08:00 EET | Press release

Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network APIs, Communications APIs, and developer tools - enabling them to copy, or fork, collections into their own workspaces and build, test, and collaborate in real time with other developers and teams. This

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release

Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto

ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo

NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye